Increasing empagliflozin dose provides significant clinical benefits in type 2 diabetes: Study - Medical Dialogues
8/18/2022 12:00:00 AM2 years 8 months ago
by Medha Baranwal
by Medha Baranwal
Japan: Switching from low-dose to high-dose SGLT2 inhibitor empagliflozin provides significant...
Japan: Switching from low-dose to high-dose SGLT2 inhibitor empagliflozin provides significant clinical benefits in patients with type 2 diabetes mellitus (T2DM), claims a recent study published in D… [+2736 chars]
full article...